Program
nemolizumab
Also written as “Nemolizumab”, “Nemolizumab 30 mg” and “nemolizumab (CIM331)”.
Its studies are mostly in Dermatitis, Atopic · Prurigo · Scleroderma, Systemic · Pruritus · Renal Insufficiency, Chronic, led by 4 companies.
Drug pageNemolizumab: every studyAll 26 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Galderma Groupits history only | 205 open or running | phase 3since Jun 11, 2019 | Mar 29, 2017 | Dec 2026phase 2 · NCT07074977 |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Oct 31, 2013 | Oct 31, 2013 | none ahead |
| Maruho | 10 open or running | phase 2since Jan 17, 2022 | Jan 17, 2022 | none ahead |
| The Skin Center Dermatology Groupits history only | 11 open or running | phase 4since Feb 1, 2026 | Feb 1, 2026 | Jun 2027phase 4 · NCT07396168 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Maruho only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 17, 2022First study: phase 2 study in Scleroderma, SystemicFirst studyNCT05214794 · 6 enrolled · Japan
TargetBeta
“Interleukin-31 receptor subunit alpha inhibitor”ChEMBL 37, by rule
Other programs on IL31RA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
The one study Maruho leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05214794Scleroderma, Systemic · Japan | 2 | Completed | Jun 4, 2024 | 6 |
How it is read
Names in the registry
- “Nemolizumab”, 20 entries
- “Nemolizumab 30 mg”, 2 entries
- “nemolizumab”, 2 entries
- “nemolizumab (CIM331)”, 1 entry
- “CD14152 Dose A”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 13 studies
- Prurigo, 5 studies
- Scleroderma, Systemic, 2 studies
- Pruritus, 1 study
- Renal Insufficiency, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.